Appili Therapeutics Inc. (APLI.TO) Research

Appili Therapeutics Inc., a Canadian biopharmaceutical firm headquartered in Halifax and founded in 2015, specializes in sourcing and advancing innovative treatments to address critical gaps in infectious disease medicine. The company's diverse pipeline includes Favipiravir, utilized for pandemic influenza and COVID-19, and the clinical-stage antifungal ATI-2307, which targets cryptococcal meningitis and invasive candidiasis. Other programs feature ATI-1503, a new class of gram-negative targeting antibiotics; ATI-1501, a taste-masked liquid oral metronidazole suspension; ATI-1801, a novel topical formulation of paromomycin for treating cutaneous leishmaniasis; and ATI-1701, a live-attenuated vaccine designed for Francisella tularensis. Additionally, Appili maintains a strategic collaboration with AiPharma Global Holdings LLC for the ongoing development of Avigan/Reeqonus (favipiravir).

Market snapshot

Symbol
APLI.TO
Price
$0.02
Day change
0.00%
Market cap
$1.9M
P/E ratio
-0.62x
52-week range
0.01-0.04
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 11 days

Peer companies

  • Algernon Pharmaceuticals Inc. (AGN.CN)
  • Aptose Biosciences Inc. (APS.TO)
  • CordovaCann Corp. (CDVA.CN)
  • Restart Life Sciences Corp. (HEAL.CN)
  • Kane Biotech Inc. (KNE.V)
  • Lifeist Wellness Inc. (LFST.V)
  • Revive Therapeutics Ltd. (RVV.CN)
  • Therma Bright Inc. (THRM.V)

Open Appili Therapeutics Inc. (APLI.TO) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.